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Pharmacological phosphodiesterase 4D (PDE4D) inhibition shows therapeutic potential to restore
memory function in Alzheimer’s disease (AD), but will likely evoke adverse side effects. As PDE4D en-
codes multiple isoforms, targeting specific isoforms may improve treatment efficacy and safety. Here, we
investigated whether PDE4D isoform expression and PDE4D DNA methylation is affected in AD and
whether expression changes are associated with severity of pathology and cognitive impairment. In post-
mortem temporal lobe brain material from AD patients (n ¼ 42) and age-matched controls (n ¼ 40), we
measured PDE4D isoform expression and PDE4D DNA (hydroxy)methylation using quantitative poly-
merase chain reaction and Illumina 450k Beadarrays, respectively. Linear regression revealed increased
PDE4D1, -D3, -D5, and -D8 expression in AD with concurrent (hydroxy)methylation changes in associ-
ated promoter regions. Moreover, increased PDE4D1 and -D3 expression was associated with high-
erplaque and tau pathology levels, higher Braak stages, and progressed cognitive impairment. Future
studies should indicate functional roles of specific PDE4D isoforms and the efficacy and safety of their
selective inhibition to restore memory function in AD.
 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Impaired memory function in Alzheimer’s disease (AD) patients
hasadebilitatingeffectondailyactivities and, consequently,negatively
affects the quality of life of patients, their caretakers, and family
(Schneider et al., 1999). The second messenger cyclic adenosine
monophosphate (cAMP) is crucial in the molecular signaling cascades
underlyingmemory function (Kandel, 2012). Intracellular cAMP levelskaerts contributed equally to
y & Neuropsychology, School
rsity, PO Box 616, 6200 MD,
x: þ31 43 3671096.
y.nl (J. Prickaerts).
Inc. This is an open access articlearemainlycontrolled throughdegradationby thephosphodiesterase4
(PDE4) enzyme family (Houslay, 2010). Accordingly, previous studies
have shown that PDE4 inhibition can improve memory consolidation
processes in rodents (Vanmierlo et al., 2016). In humans, the PDE4
inhibitor roflumilast was found to enhance verbal learning in young
adults and old healthy volunteers (Blokland et al., 2019; Van Duinen
et al., 2018). Thus, PDE4 inhibition seems to hold clinical potential as
a treatment toenhancememory functioning. The therapeuticpotential
in AD is supported by the finding that PDE4 inhibition can restore
memory impairments induced by intra-hippocampal injections with
amyloid-b in rats (Cheng et al., 2010). Moreover, in a mouse model of
tauopathy, the number of tau aggregates was reduced after adminis-
tration of the nonselective PDE4 inhibitor rolipram (Myeku et al.,
2016). Despite these promising results, progression of new PDE4under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Demographic characteristics of the cohort
Characteristic Non-demented controls AD patients
Gender (male/female) 20/20 19/23
APOE ε4 (present/absent) 9/31 27/15
Braak stage (I-II/III-IV/V-VI) 16/24/0 0/14/28
Age, mean (SD) 84.3 (5.81) 85.1 (6.49)
PMI, mean (SD) 2.77 (0.75) 2.75 (0.73)
Key: AD, Alzheimer’s disease; PMI, post-mortem interval; SD, standard deviation.
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limiting side effects, mainly nausea and emesis. More selective inhi-
bition of PDE4 subtypes or isoforms may circumvent these adverse
effects. In the present study, we investigated whether expression
regulation of PDE4D isoforms is altered inADbrainmaterial to identify
potential targets for more selective PDE4 inhibition. The PDE4 family
consists of 4 genes (PDE4A-D) of which PDE4D seems to be mostly
involved in the modulation of cognitive functions (Zhang et al., 2017).
Hence, inhibitors selective for PDE4D have been developed to inves-
tigate their cognition-enhancing potential. These newselective PDE4D
inhibitors have been found to enhance memory performance in ro-
dents, including models of AD (Ricciarelli et al., 2017; Zhang et al.,
2018). The procognitive effects of PDE4D-specific inhibition are sup-
ported by PDE4D knock-down studies (Baumgartel et al., 2018). The
memory-enhancing potential of PDE4D inhibition has also been tested
in Phase I clinical trials (ClinicalTrials.gov Identifier: NCT02648672 and
NCT02840279) and currently, preparations are under way to initiate a
Phase II trial in patients with early-stage AD (ClinicalTrials.gov Iden-
tifier: NCT03817684). Notably, PDE4D inhibition is also hypothesized
to induce emetic side effects given its expression in brain areas
involved in emesis, that is, the area postrema, and based on gene
deletion studies (Mori et al., 2010; Robichaud et al., 2002). The human
PDE4D gene gives rise to multiple protein isoforms, that is, PDE4D1-9,
through alternative promoters and alternative splicing. These isoforms
regulate amultitude of different processes and are localized to specific
compartments within the cell owing to specific amino acids in the N-
terminal domain (Houslay, 2010; Houslay et al., 2007). Hence, by
inhibiting specific PDE4D isoforms, it can be argued that memory-
enhancing effects could be retained without evoking side effects
(Schepers et al., 2019). Despite the potential of PDE4D isoform-specific
inhibition as a safe and efficacious treatment strategy in AD, the role of
PDE4D isoforms in the context of specific brain functions or AD has
only sporadically been described (McLachlan et al., 2007; Perez-Torres
et al., 2000; Ugarte et al., 2015).
PDE4D isoforms showing high or increased expression in AD
could be interesting targets, as these isoformsmay contribute largely
to cAMP hydrolysis and consequently impede memory functioning.
PDE4D isoform expression is likely controlled by epigenetic mech-
anisms to regulate, for example, isoform-specific promoter accessi-
bility. Previous research indicated that epigenetic modifications at
the histone level influence promoter accessibility in the PDE4D gene
and consequently affect isoform-specific expression in vascular
smooth muscle cells (Tilley and Maurice, 2005). At the nucleotide
level, epigenetic processes can reversibly influence transcription
through conversion of unmethylated cytosines (UC) into methylated
(5mC) or hydroxymethylated (5hmC) cytosines. Specific changes in
DNA methylation and hydroxymethylation have previously been
associated with AD (Smith et al., 2019). Recently, PDE4D was found
those genes displaying differentially methylated in AD in an
epigenome-wide association study (Lardenoije et al., 2019).
To investigate whether PDE4D isoform expression is altered in
AD and whether this is associated with epigenetic changes at spe-
cific positions in the PDE4D gene, we established PDE4D expression
and epigenetic profiles of human post-mortem brain material of AD
patients and age-matched controls. Since AD is a progressive dis-
ease, we also explored whether changes in expression were asso-
ciatedwith region-specific plaque and tau load, Braak stage, and the
degree of cognitive impairment.
2. Methods
2.1. Brain material and study cohort
Informed consent was obtained from all individual participants
included in the study. Human post-mortem brain material from themiddle temporal gyrus (MTG) of AD patients and neurologically
healthy controls was obtained from the Banner Sun Health Research
Institute in Sun City, AZ. For every sample information onMini-Mental
State Examination (MMSE) score (Folstein et al., 1975), gender, age,
post-mortem interval (PMI), APOE ε4 possession, amyloid-b plaque
load, tau tangle load, Braak stage, and diagnosis were documented
and tissue was prepared by standardized procedures (Beach et al.,
2015). Braak staging was evaluated as previously described (Braak
and Braak, 1991). AD diagnostic criteria followed guidelines for the
National Institute on Aging-Reagan Institute criteria (Consensus
Recommendations for the Postmortem Diagnosis of Alzheimer’s
Disease, 1997) combined with clinical diagnosis reports. Samples
collected after a PMI of more than 5 hours and samples from patients
with comorbidities were excluded. A total of 82 samples were
included from AD patients (n ¼ 42) and age- and gender-matched
neurologically healthy controls (n ¼ 40) with an average PMI of
2.8 hours. For subsequent analysis investigating associations between
expression andMMSE score, cases forwhich cognitive performance in
the MMSE was assessed longer than 36 months before death were
excluded, leaving a subset of 41 cases. A detailed description of the
cohort demographics can be found in Table 1.
2.2. RNA isolation, complementary DNA synthesis, and qPCR
Total RNA was isolated from frozen MTG tissue using the TRIzol
Plus RNA Purification Kit (Life Technologies, Carlsbad, CA) following
the manufacturer’s protocol. Isolated RNA pellets were dissolved in
RNAse-free water and assessed for quantity and quality (average
RIN: 9.1) using a Nanodrop ND-1000 spectrophotometer (Thermo
Scientific, DE) and Bioanalyzer (Agilent). Then, complementary
DNAwas synthesized using the Revert Aid First Strand Synthesis Kit
(Thermo Scientific, Landsmeer, Netherlands) according to the
manufacturer’s protocol.
TaqMan-based quantitative polymerase chain reaction (qPCR)
primers were used for the following PDE4D isoforms: PDE4D2,
PDE4D4, PDE4D5, PDE4D6, PDE4D8, and PDE4D9 (Applied Bio-
systems, Foster City, CA, USA). PDE4D2 could not be detected.
Primers were designed for PDE4D1, PDE4D3, and PDE4D7 as no
TaqMan-based qPCR primers were available for these isoforms
(SIGMA Life Science). Housekeeping gene expression of EIF4A2 and
TOP1 showed the most stable expression based on geNorm criteria
and was used for normalization (Vandesompele et al., 2002). Taq-
Man probe and primer sequences are listed in Table 2. TaqMan-
based qPCR was performed using TaqMan Assay 20x and TaqMan
Universal Master Mix II, with UNG 2x (Applied Biosystems)
following the manufacturer’s protocol. For qPCR using primers,
SensiMix 2X (Bioline) was used according to the manufacturer’s
protocol. All reactions were performed using 6 ng complementary
DNA on a LightCycler 480 (Roche).
2.3. Tissue preparation for (hydroxy)methylomic profiling
DNA was isolated from the MTG at the Banner Sun Health
Research Institute. From 81 of the 82 subjects, a total of 76 mg of
Table 2
TaqMan probe and primer sequences
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at 55 C in lysis buffer (100 mM Tris-HCl pH 8.5, 200 mM NaCl,
5 mM ethylenediaminetetraacetic acid, 100 mg/mL Proteinase K
[Sigma-Aldrich, St. Louis, MO], and 0.2% sodium dodecyl sulfate)
and homogenized in a pellet mixer (Kontes). After addition of RNase
(Qiagen, Valencia, CA, USA), DNA was isolated by means of phenol/
chloroform (Sigma) extraction followed by ethanol precipitation
and resuspension in TE buffer (pH 8.0). Ultimately, DNA samples
were quantified and checked for purity by means of
spectrophotometry.2.4. Oxidative bisulfite conversion and DNA (hydroxy)methylation
assay
The (oxidative) bisulfite (oxBS) conversion procedures and
HumanMethylation450 BeadChip array were carried out at Serv-
iceXS (ServiceXS B.V., Leiden, the Netherlands), in accordance to the
manufacturer’ protocols and as described previously (Lardenoije
et al., 2019). Briefly, a TrueMethylTM 24 kit version 2.0 by
CEGXTM (Cambridge Epigenetix Limited, Cambridge, UK) was used
to convert the isolated genomic DNA (gDNA) by bisulfite (BS) or
oxBS treatments to detect and localize 5mC and 5hmC marks at
single-base resolution. Before conversion, gDNA quality was
assessed using a PicoGreen assay (Invitrogen, Carlsbad, CA, USA)
and high molecular weight gDNA was quantified by gel-
electrophoresis. Upon purification and denaturation, high molecu-
lar weight gDNA (0.5 mg per treatment) was used for DNA oxidation
or mock DNA oxidation treatments followed by BS conversion. DNA
yield was assessed by Qubit ssDNA assay (Invitrogen) and qualita-
tive assessment of 5hmC oxidation and BS conversion was per-
formed using a restriction quality control. Then, 8 mL of each DNA
sample was used for amplification and hybridization on the
HumanMethylation450 BeadChip (Illumina, Inc., San Diego, CA,
USA) according to the Illumina “Infinium II Methylation Assay
Manual” protocol. Eventually, the Illumina iScan was used to scan
the samples.2.5. Processing of DNA (hydroxy)methylation assay data
For (hydroxy)methylomic profiling, data were processed and
analyzed using R statistical programming language (version 3.5.3)
(R Development Core Team, 2019) and RStudio (version 1.2.1335)
(RStudio Team, 2019). The minfi package (version 1.28.4) was used
to load raw IDAT files from the Illumina iScan (Aryee et al., 2014).
Probes that cross-hybridize, locate to X and Y chromosomes and
probes binding within 10 bp of a common SNP location were
removed (Chen et al., 2013). Remaining probes were filtered using
the “pfilter” function of the wateRmelon package (version 1.26.0)(6414 probes were removed) (Pidsley et al., 2013). Data from
397,160 remaining probes were split into 2 sets of beta values ac-
cording to the oxBS and BS arrays, representing 5mC and 5mC þ
5hmC, respectively. These data were dasen normalized using the
wateRmelon package (Pidsley et al., 2013). The maximum likeli-
hoodmethylation levels (MLML) method was used, bymeans of the
“MLML” function within the MLML2R package (version 0.3.2), to
calculate the proportions of 5mC, 5hmC, and UC by combining the
signal from the BS and oxBS arrays as input (Kiihl et al., 2019; Qu
et al., 2013). Subsequently, probes showing either a 5hmC value
of zero in at least half of the cases or BS beta value lower than 0.1
were filtered out (112,697 5hmC values were excluded). Data dis-
tributions of raw and normalized beta values per sample were
visualized in boxplots and density plots to identify outliers (3
samples were excluded due to clear deviation from the other
samples; data not shown). Datawere processed again upon removal
of these outliers.
After data processing, 78 samples remained, with 397,160
remaining probes for 5mC and UC, and 284,463 5hmC probes. Data
were split into 2 sets of beta values according to the oxBS and BS
arrays, representing 5mC and 5mC þ 5hmC, respectively.
2.6. Statistical analysis
Raw expression data from the LightCycler 480 were analyzed
using LinRegPCR to determine logarithmic fluorescence values at
cycle zero (Ruijter et al., 2009). qPCR reactions that did not show
fluorescent signal amplification were excluded from further anal-
ysis. Logarithmic fluorescence values were normalized against the
average expression of reference genes TOP1 and EIF4A2. Normalized
data followed a Gaussian distribution and were used for statistical
analysis.
For expression data, linear regression analyses were performed
using IBM SPSS Statistics for Windows, Version 25.0 (IBM Corp.,
Armonk, NY) with normalized starting fluorescence values per
isoform as dependent variable and diagnosis (control ¼ 0, AD ¼ 1,
respectively), plaque load in the temporal lobe (0-3), tangle load in
the temporal lobe (0-3), Braak stage level (Braak I-II ¼ 0, Braak III-
IV ¼ 1, and Braak V-VI ¼ 2), or MMSE score (0e30) as independent
variable. Age, gender, PMI, APOE ε4 possession, and qPCR plate were
included as covariates. Unstandardized regression coefficients were
exponentially transformed to calculate the fold expression change
in AD. p values were Bonferroni-corrected by multiplying p values
by the number of dependent variables (i.e., expression of isoforms)
tested per model, and values smaller than 0.05 were considered
statistically significant.
For (hydroxy)methylomic data, a surrogate variable (SV) analysis
was donewith the sva package (version 3.30.1) (Leek et al., 2012) on
an initial linear regression model with beta values as dependent
variable, diagnosis as independent variable, and age, gender, PMI,
and APOE ε4 possession as covariates. To adjust for unobserved
confounders, the first 5 SVs of the SV analysis were included in the
regression model. Linear regression was performed using the
limma package (version 3.38.3) (Ritchie et al., 2015). Adjustment for
bias and inflation of test statistics was done with the bacon package
(version 1.10.1) (van Iterson et al., 2017). To explore whether
isoform-specific expression changes could be mechanistically
explained by specific epigenetic changes, only probes that locate
closest to PDE4D isoform promoters showing significant expression
changes (i.e., PDE4D1, -D3, -D5 and -D8) were selected (24 probes).
Nominal significance for DNA methylation changes between AD
cases and controls was set at p-value <0.05. Diagnosis-associated
methylation changes were investigated further by follow-up
linear regression analyses using the same model, but instead of
diagnosis, using plaque load in the temporal lobe (0e3), tangle load
Table 3









PDE4D1 82 0.383 0.013 2.99
PDE4D3 82 0.435 0.002 3.85
PDE4D4 67 0.259 0.487 2.14
PDE4D5 67 0.356 0.040 2.56
PDE4D6 77 0.267 0.257 2.90
PDE4D7 82 0.309 0.091 2.82
PDE4D8 62 0.394 0.045 3.85
PDE4D9 77 0.249 0.212 2.24
Linear regression analyses were performed according to the following formula:
Expression ¼ Intercept þ Diagnosis þ Gender þ Age þ APOE ε4 possession þ PMI þ
qPCR plate. Significance levels are Bonferroni-corrected for the number of depen-
dent variables tested. p values and fold changes are rounded to 3 and 2 decimals,
respectively.
Key: AD, Alzheimer’s disease; MTG, middle temporal gyrus; PDE4D, phosphodies-
terase 4D; PMI, post-mortem interval; qPCR, quantitative polymerase chain
reaction.
D. Paes et al. / Neurobiology of Aging 97 (2021) 56e64 59in the temporal lobe (0-3), Braak stage level (Braak I-II¼ 0, Braak III-
IV ¼ 1, and Braak V-VI ¼ 2), or MMSE score (0e30) as predictor
variable. False discovery rates for these predictors’ p values were
determined by the Benjamini-Hochberg procedure.3. Results
3.1. Increased PDE4D isoform expression in Alzheimer’s disease
Linear regression analyses revealed that AD diagnosis was
significantly associated with increased expression levels of PDE4D1,
-D3, -D5, and -D8, in the range of 2.56- to 3.85-fold increased
expression (p < 0.05; Table 3).3.2. Differential epigenetic signatures in PDE4D promoter regions in
Alzheimer’s disease
As PDE4D was found to be differentially methylated in AD in an
epigenome-wide association study using the same tissue
(Lardenoije et al., 2019), as an exploratory approach, we investi-
gated whether 5'-cytosine-phosphate-guanine-3' sites within the
promoter regions of differentially expressed PDE4D1, -D3, -D5, -D8
were subject to methylation differences. Twenty-four of the epi-
genome-wide association study assay probes located to these pro-
moters and allowed the assessment of the methylation status (5mC,
5hmC, or UC) of specific 5'-cytosine-phosphate-guanine-3' sites.
Linear regression analyses revealed diagnosis-dependentTable 4
CpG sites in specific PDE4D promoter regions showing altered methylation status in AD
Promoter N CpG probe Status Fold cha
PDE4D1 78 cg19539826 UC 0.9871
PDE4D3 78 cg13112511 5mC 0.9818
78 cg13112511 5hmC 1.0197
PDE4D5 78 cg03653541 5mC 1.0023
78 cg14784398 5mC 0.9958
78 cg12519013 5mC 0.9965
78 cg14784398 UC 1.0035
78 cg03653541 UC 0.9972
PDE4D8 78 cg23987137 5mC 1.0144
78 cg23987137 5hmC 0.9812
78 cg17584009 5hmC 1.0162
Linear regressions were performed according to the following formula: Methylation st
surrogate variables.
Key: 5hmC, 5-hydroxymethylcytosine; 5mC, 5-methylcytosine; AD, Alzheimer’s disease;
UC, unmethylated cytosine.methylation status differences in each of the promoters. The 5'-
cytosine-phosphate-guanine-3' sites for which methylation status
was associated with diagnosis are shown in Table 4. AD-associated
effects on methylation status appear to be different per promoter
region. For example, in the PDE4D3 promoter, at position
cg13112511, AD diagnosis was associated with decreased 5mC (fold
change [FC] ¼ 0.9818, p < 0.05) and increased 5hmC (FC ¼ 1.0197, p
< 0.05) levels. Contrastingly, increased 5mC (FC ¼ 1.0144, p < 0.01)
and decreased 5hmC (FC ¼ 0.9812, p < 0.05) levels were found in
the PDE4D8 promoter at cg23987137 in AD cases. Within the
PDE4D5 promoter, effects with opposite directionality were found;
increased 5mC and decreased UC levels were detected in AD cases
at position cg03653541 (5mC: FC ¼ 1.0023, p < 0.05 and UC: FC ¼
0.9972, p < 0.05), while position cg14784398 indicated decreased
5mC (FC ¼ 0.9958, p < 0.05) and increased UC (FC ¼ 1.0035, p <
0.05) levels. These findings suggest that AD is associated with
PDE4D DNA (hydroxy)methylation changes that are promoter- and
site-specific, concomitant with expression changes of the corre-
sponding isoforms.
3.3. PDE4D isoform expression is associated with AD pathology and
cognitive impairment
For isoforms showing different expression between AD and
controls (i.e., PDE4D1, -D3, -D5, and -D8), linear regression analyses
were performed to investigate whether expression was associated
with the degree of pathology or cognitive impairment. Higher levels
of plaque pathology in the temporal lobe were associated with
increased PDE4D1 and -D3 expression (p < 0.05), while tangle
pathology in the temporal lobe was associated with increased
expression of PDE4D1 (p< 0.05), PDE4D3 (p< 0.01), and PDE4D5 (p
< 0.05; Table 5 and Fig. 1). In addition, Braak staging associated
significantly with increased expression of PDE4D1 (p < 0.05) and
PDE4D3 (p < 0.001). Additionally, we examined the association
between isoform expression and the level of cognitive impairment
as assessed by the MMSE. Lower MMSE scores were significantly
associatedwith increased expression of PDE4D1 (p< 0.01), PDE4D3
(p < 0.01), and PDE4D5 (p < 0.05; Table 5 and Fig. 1). These results
indicate that increased expression, of mainly the PDE4D1 and
PDE4D3 isoforms, correlates with higher pathology levels andmore
severe cognitive impairment.
3.4. PDE4D promoter methylation is associated with AD pathology
and cognitive impairment
The diagnosis-dependent methylation changes as determined in
Table 4 were investigated further for their potential associationnge in AD Mean t df p-value
0.5871 2.363 67 0.018
0.3211 2.571 67 0.010
0.0537 2.299 67 0.022
0.0729 2.402 67 0.016
0.1267 2.330 67 0.020
0.0849 1.970 67 0.049
0.8722 2.098 67 0.036
0.9178 2.010 67 0.044
0.3957 2.833 67 0.006
0.1765 2.391 67 0.017
0.2300 1.961 67 0.050
atus ¼ Intercept þ Diagnosis þ Gender þ Age þ APOE ε4 possession þ PMI þ five
df, degrees of freedom; PDE4D, phosphodiesterase 4D; PMI, post-mortem interval;
Table 5









Isoform N Plaque load Tangle load Braak stage N MMSE
PDE4D1 82 0.313a 0.352a 0.445a 41 0.577b
PDE4D3 82 0.332a 0.374b 0.508c 41 0.610b
PDE4D5 67 0.207 0.344a 0.315 33 0.475a
PDE4D8 62 0.211 0.203 0.178 32 0.448
Linear regressions were performed according to the following formula:
Expression ¼ Intercept þ Pathology variable (i.e., plaque load, tangle load, Braak) or
MMSE þ Gender þ Age þ APOE allele ε4 possession þ PMI þ qPCR plate. Cases for
which MMSE scores were assessed more than 36 mo before death were excluded.
Significance levels Bonferroni-corrected for the amount of dependent variables
tested.
Key: MMSE, Mini-Mental State Examination; PDE4D, phosphodiesterase 4D; PMI,
post-mortem interval; qPCR, quantitative polymerase chain reaction.
a p < 0.05.
b p < 0.01
c p < 0.001.
D. Paes et al. / Neurobiology of Aging 97 (2021) 56e6460with the degree of pathology or cognitive impairment by means of
linear regression analyses. These analyses revealed significant as-
sociations between methylation status changes and pathology or
cognitive impairment in accordance to the directionality of changes
observed between AD cases and controls. In the PDE4D3 promoter,
both decreased 5mC (hypomethylation) and increased 5hmC
(hyperhydroxymethylation) at CpG site cg13112511 were found to
associate with an increased plaque load and a higher Braak stage
(Table 6). Contrarily, in the PDE4D8 promoter, increased 5mC and
decreased 5hmC at position cg23987137 was associated with
increased pathology levels. Methylation status in the PDE4D5
promoter also associated with levels of pathology but the direc-
tionality of methylation status change was different per CpG site
(e.g., cg03653541 shows increased 5mC, while cg12519013 shows
decreased 5mC with higher levels of pathology; Table 6). Finally,
lower MMSE scores were associated with increased 5mC levels in
the PDE4D5 promoter (cg03653541) and PDE4D8 promoter
(cg23987137).4. Discussion
Inhibition of PDE4D has been shown to hold promise as an
effective strategy to enhance memory in humans (clinical trials
NCT02648672 and NCT02840279), but is also assumed to
contribute to possible emetic side effects upon non-selective PDE4
inhibition (Giembycz, 2002; Mori et al., 2010). The PDE4D gene
encodes multiple isoforms that, for example, by specific intracel-
lular localization, can regulate different compartmentalized pools
of cAMP (Houslay et al., 2007). Hence, targeting specific PDE4D
isoforms may provide a safer and more efficacious treatment
strategy to alleviate memory deficits in AD without evoking side
effects (Schepers et al., 2019). To investigate which specific PDE4D
isoform(s) is/are altered in terms of expression in AD, we estab-
lished PDE4D isoform expression profiles in post-mortem MTG
tissue derived from AD patients and healthy non-demented con-
trols by means of isoform-specific qPCR.
Regression analyses revealed that AD was associated with
increased expression of PDE4D1, -D3, -D5, and -D8. Expression of
these isoforms was increased in the range of 2.56- to 3.85-fold.
Previous studies have indicated that 3- to 4-fold increased PDE4D
(isoform) mRNA expression results into similar increases in both
PDE4D protein expression and PDE4 activity (Levallet et al., 2007;
Peter et al., 2007). Therefore, the 2.59- to 3.85-fold expressionincreases likely increase PDE4 activity. To our knowledge, the
number of studies investigating PDE4D expression in light of AD is
limited. Ugarte et al. (2015) did not find a difference in overall
PDE4D expression in temporal lobe material from AD patients (n ¼
7) and controls (n ¼ 8). McLachlan et al. (2007) investigated hip-
pocampal PDE4D isoform expression in material from a single pa-
tient with advanced AD and 3 control cases and found a 2.62-fold
increase in PDE4D1 expression, while the expression of other iso-
forms was reduced or unaffected. Our study, making use of a much
larger sample size, shows, in addition to a similar increase in
PDE4D1 expression, increased expression of PDE4D3, -D5, and -D8.
The current findings imply that PDE4D expression is affected in AD
in an isoform-specific manner.
Because AD is a progressive disease, we also inspected whether
PDE4D isoform expression increases with higher degrees of pa-
thology or more severe cognitive impairment. Expression of
PDE4D1 and PDE4D3 was associated with temporal plaque load,
temporal tangle load, Braak staging, as well as cognitive impair-
ment. PDE4D5 expression was found to be only associated with
temporal tangle load and cognitive impairment, while PDE4D8
expression was not associated with any pathology measure or
cognitive impairment. These findings suggest that mainly PDE4D1
and PDE4D3 expression changes as the disease progresses and
cognitive impairment worsens. The observation that PDE4D3
transcription is increased in presence of higher amyloid-b plaque
load corresponds to earlier findings. Hippocampal injections of Ab1-
42 in mice causedmemory deficits and increased protein expression
of PDE4D3, which was reversed upon non-selective PDE4 inhibition
by resveratrol (Wang et al., 2016). Interestingly, Olah et al., (2011)
found a direct interaction between oligomeric Ab and PDE4D.
Whether this interaction occurs in vivo and how this interaction
affects PDE4D enzymatic activity remains to be determined. From a
potentially therapeutic perspective, it would be interesting to
identify whether inhibition of PDE4D1 and/or PDE4D3 specifically
can delay disease progression and improve cognitive functioning.
As the PDE4D gene, with its various isoforms embedded, con-
tains multiple promoter regions, epigenetic mechanisms are likely
involved in its isoform-specific expression regulation, for example,
by influencing promoter accessibility (Maunakea et al., 2010; Tilley
and Maurice, 2005). Here, we found that DNA (hydroxy)methyl-
ation signatures in the promoter regions of PDE4D1, -D3, -D5, and
-D8 were altered in the same tissue as used for the expression
profiling. Results showed differentially methylated CpG sites in
these promoters that were associated with AD diagnosis. Moreover,
methylation status was also associated with the degree of pathol-
ogy and cognitive impairment for several CpG sites. Various effects
were observed, that is, both increased and decreased 5mC, 5hmC,
and UC levels. Differences in methylation and hydroxymethylation
can be linked to altered gene expression by affecting the binding of
transcription factors and chromatin proteins to the DNA (Suzuki
and Bird, 2008; Yin et al., 2017). As such, decreased methylation
and increased hydroxymethylation in AD in the PDE4D3 promoter
might explain, at least in part, the observed pathology- and AD-
associated increased expression of PDE4D3. In contrast, in the
PDE4D8 promoter, cg23987137 displayed AD-associated hyper-
methylation and hypohydroxymethylation. However, cytosine
methylation can have differential effects on transcription factor
binding and subsequent gene expression. Interestingly, cg23987137
is located 14 nucleotides downstream of an activator protein 1 (AP-
1) binding site (Farre et al., 2003). The transcription factor AP-1 is
usually described as a transcriptional activator, but can also act as
transcriptional repressor (Brellier et al., 2004). Moreover, it has
been shown that methylation adjacent to, but not within, the AP-1
binding site can hamper AP-1 binding and consequently induce
transcription (Fujimoto et al., 2005). Although purely speculative, a
Fig. 1. Association of pathology and cognitive impairment level with PDE4D isoform expression. (A) Partial regression plots visualizing the associations between PDE4D isoform
expression and the degree of pathology (plaque and tangle load in the temporal lobe, and Braak stage level) or cognitive impairment (MMSE score), corrected for gender, age, APOE
allele ε4 possession, PMI, and qPCR plate. Marker types reflect the diagnosis status of the cases (blue circles: controls, red squares: AD cases). (B) Overview of slope values (b) and
squared correlation coefficients of the regression lines in the partial regression plots in panel A. b values correspond to the unstandardized coefficients of pathology and MMSE
variables in the regressions according to the formula described in Table 5. Significance levels Bonferroni-corrected for the amount of dependent variables tested; *p < 0.05, **p <
0.01, ***p < 0.001. Abbreviations: AD, Alzheimer’s disease; CTRL, control; MMSE, Mini-Mental State Examination; PDE4D, phosphodiesterase 4D; PMI, post-mortem interval; qPCR,
quantitative polymerase chain reaction. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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promoter resulting in increased expression upon CpG site hyper-
methylation. Similarly, epigenetic changes observed in the other
promoters can, by influencing binding of transcriptional activators
and repressors, induce increased expression of the associated iso-
forms. Interestingly, increased methylation at cg23987137 PDE4D8
promoter was associated with worse cognitive performance while
PDE4D8 expression did not associate with cognitive performance.
This discrepancy may suggest that DNA methylation may not solely
influence expression via its closest located promoter but may also
regulate expression of other isoforms which do show associations
with cognitive performance (i.e., PDE4D1, -D3, and -D5).The current findings show that in AD, expression of specific
PDE4D isoforms is altered with concurrent changes (hydroxy)
methylation changes in associated promoters of the PDE4D gene.
Although PDE4D isoforms locate to specific cellular compartments,
the role of individual PDE4D isoforms in specific cellular processes
is still largely unknown. The mouse orthologue of PDE4D1 is re-
ported to localize to the nucleus (Chandrasekaran et al., 2008).With
95.6% homology in the N-terminal, human PDE4D1 may share a
similar localization signal and hence could be involved in the
regulation of nuclear cAMP levels which may directly affect PKA-
CREB mediated transcription crucial for memory consolidation
(Kandel, 2012). Transgenic overexpression of PDE4D1 in specific
Table 6
Significant associations of PDE4D promoter methylation status with pathology and cognitive impairment
Promoter CpG probe Status N Variable Fold change Mean t df p-value FDR
PDE4D3 cg13112511 5mC 78 Plaque 0.9917 0.3211 2.561 67 0.010 0.017
78 Braak 0.9858 0.3211 2.929 67 0.003 0.008
5hmC 78 Plaque 1.0095 0.0537 2.456 67 0.014 0.042
78 Braak 1.0167 0.0537 2.674 67 0.007 0.011
PDE4D5 cg03653541 5mC 78 Tangle 1.0010 0.0729 2.805 67 0.005 0.025
78 Braak 1.0014 0.0729 2.104 67 0.035 0.035
39 MMSE 0.9997 0.0732 3.533 28 <0.001 0.001
UC 78 Plaque 0.9984 0.9178 2.533 67 0.011 0.034
cg14784398 5mC 78 Tangle 0.9983 0.1267 2.363 67 0.018 0.030
78 Braak 0.9972 0.1267 2.200 67 0.028 0.035
UC 78 Plaque 1.0015 0.8722 2.175 67 0.030 0.044
cg12519013 5mC 78 Plaque 0.9980 0.0849 2.612 67 0.009 0.022
78 Tangle 0.9985 0.0849 2.157 67 0.031 0.039
78 Braak 0.9973 0.0849 2.202 67 0.027 0.046
PDE4D8 cg23987137 5mC 78 Plaque 1.0063 0.3957 2.791 67 0.005 0.026
78 Tangle 1.0047 0.3957 2.384 67 0.017 0.043
78 Braak 1.0108 0.3957 3.034 67 0.002 0.012
39 MMSE 0.9987 0.4035 4.126 28 <0.001 <0.001
5hmC 78 Plaque 0.9922 0.1765 2.178 67 0.029 0.044
78 Braak 0.9851 0.1765 2.735 67 0.006 0.019
Linear regressions were performed according to the following formula: Methylation status ¼ Intercept þ Pathology variable (i.e., plaque load, tangle load, Braak) or MMSE þ
Gender þ Age þ APOE ε4 possession þ PMI þ five surrogate variables. Cases for which MMSE scores were assessed more than 36 mo before death were excluded.
Key: 5hmC, 5-hydroxymethylcytosine; 5mC, 5-methylcytosine; df, degrees of freedom; FDR, false discovery rate (Benjamini-Hochberg); MMSE, Mini-Mental State Exami-
nation; PDE4D, phosphodiesterase 4D; UC, unmethylated cytosine.
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a specific role for this isoform in neuronal firing (Yoshida et al.,
2003). Increased PDE4D1 expression in AD may therefore
decrease neuronal firing rates that subsequently impacts neuronal
plasticity and memory formation processes.
Specific interactions have been reported between PDE4D3 and
A-kinase anchoring proteins (AKAPs), for example, AKAP9 and
mAKAPa, through which PDE4D3 can locally degrade cAMP pools
(Boczek et al., 2019; Terrenoire et al., 2009). Disrupting the peri-
nuclear PDE4D3-mAKAPa signaling complex promoted survival
and axon growth in neurons (Boczek et al., 2019). Vice versa,
increased PDE4D3 expression as observed in the current study
could hamper these effects, thereby likely impairing neuronal
plasticity and memory processes in AD.
Similar to PDE4D3-AKAP interactions, the scaffolding protein b-
arrestin was found to preferentially interact with PDE4D5 (Baillie
et al., 2007). b-arrestin is recruited to G-protein coupled receptors
(GPCRs) upon activation, which places PDE4D5 in close proximity to
sites where cAMP is produced, that is, close to GPCRs and activated
adenylyl cyclases that produce cAMP (Baillie et al., 2003; Houslay
and Baillie, 2005). Increased PDE4D5 levels may therefore exces-
sively degrade cAMP at the site of synthesis. Vice versa, down-
regulation of PDE4D5 may stimulate cAMP signaling, which is
supported by the interesting finding that knockdown of PDE4D4 or
PDE4D5 can improve memory performance in mice (MacKenzie
et al., 2011; Wang et al., 2013). In addition to cytosolic interactions,
it was found that PDE4D5 also regulates cAMP levels in nuclear
signaling complexes, indicating that a specific isoform can regulate
cAMP levels in spatially distinct compartments (Clister et al., 2019).
Regarding PDE4D8, most insights have been gathered through
cardiovascular research. In cardiomyocytes, PDE4D8 is located near
the b1-adrenergic receptor through a SAP97-mediated interaction
and dissociates upon receptor stimulation (Fu et al., 2014; Richter
et al., 2008). As SAP97 is a synapse-associated protein that scaf-
folds multiple receptors, including AMPA receptors crucial for
memory processes, similar interactions may occur in the brain
(Zhang et al., 2015). Moreover, PDE4D8 is found to localize in
leading-edge structures of migrating vascular smooth muscle cells
and affects actin organization upon overexpression (Raymond et al.,
2009). Actin-rich leading edges in neuronal or glial cells may also beaffected by increased PDE4D8 levels and consequently induce
dysfunctional migration and growth, possibly contributing to
impaired cognitive functioning eventually.
Through their specific localizations, the isoforms PDE4D3, -D5,
and -D8 have all been reported to modulate downstream signaling
of b-adrenergic receptors (Baillie et al., 2003; De Arcangelis et al.,
2009; Richter et al., 2008). As adrenergic signaling is involved in
cognitive functioning and can be affected in AD (Gannon et al.,
2015), changes in expression of PDE4D isoforms may disrupt
downstream b-adrenergic signaling leading to cognitive dysfunc-
tion. In sum, upcoming studies will have to indicate isoform-
specific roles in memory processes, so local cAMP compartments
can be targeted and treatment efficacy can be increased.
Finally, the current findings represent PDE4D isoform expres-
sion and DNA (hydroxy)methylation in homogenized brain tissue,
meaning no conclusions can be drawn yet on potential cell type-
specific effects. Hence, follow-up studies will have to indicate
whether the current findings can be linked to changes in specific
cell types (e.g., neurons, microglia, astrocytes, oligodendrocytes,
endothelial cells). Also, whether increased PDE4D expression is
causal to or a consequence of worsening pathology remains to be
specified. Nevertheless, these findings highlight isoform-specific
PDE4D inhibition as a potential strategy to aid in delaying disease
progression with associated procognitive effects.5. Conclusions
Taken together, regulation of PDE4D transcription is affected in
AD as indicated by differences in gene (hydroxy)methylation and
expression levels. Moreover, the specific isoforms PDE4D1 and
PDE4D3 show a significant associationwith the degree of pathology
and cognitive impairment. In linewith the fact that PDE4D isoforms
regulate specific intracellular processes, this implies that targeting
specific PDE4D isoforms may provide a more efficacious treatment
strategy with less adverse effects in different stages of the disease.
For this purpose, future studies will have to reveal which PDE4D
isoforms regulate mechanisms underlying memory enhancement
and do not show adverse effects upon inhibition in the context of
brain function in both health and AD.
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